• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Progesterone, Cerclage or Pessary for Prevention of Preterm Birth: A Comparison

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Jarde et al. (BJOG, 2018) compared different types and routes of administration of progesterone, cerclage, and pessary for preterm birth prevention 

METHODS: 

  • Systematic review and meta-analysis  
    • Included RCTs  
    • Population: At-risk women based on preterm birth, short cervix or other risk factors (as determined by researchers)  
      • Cerclage (any type) | Pessary | Progesterone (any route) 
      • Interventions were compared to controls or other specified interventions  
  • Primary outcomes  
    • Preterm birth (PTB) <37 week and preterm birth <34 weeks and overall  
  • Secondary outcomes 
    • Neonatal death   
    • Other adverse maternal and newborn outcomes  
  • Statistical analysis 
    • Bayesian random-effects network meta-analyses with 95% credibility intervals (CrI) as well as pairwise meta-analyses and confidence intervals (CI)  
  • Assessed evidence quality using GRADE methods

RESULTS: 

  • 40 trials | 11,311 women 

In at-risk women overall (any risk factor)  

  • Vaginal progesterone reduced PTB and risk of neonatal death  
    • PTB <34 weeks: Odds ratio (OR) 0.43 (95% CrI, 0.20–0.81; low quality evidence) 
    • PTB <37 weeks: OR 0.51 (95% CrI, 0.34–0.74; low quality evidence) 
    • Neonatal death: OR 0.41 (95% CrI, 0.20–0.83; moderate quality evidence) 
  • IM 17-OHPC reduced PTB 
    • PTB <37 weeks: OR 0.61 (95% CrI, 0.39-0.92; Moderate quality evidence)  
  • Pessary reduced risk of PTB  
    • PTB <37 weeks: OR 0.31 (95% CrI, 0.13-0.82 (very low quality evidence)  

Previous PTB 

  • Vaginal progesterone reduced PTB  
    • PTB <34 weeks: OR 0.29 (95% CI, 0.12–0.68; moderate quality evidence) 
    • PTB <37 weeks: OR 0.43 (95% CrI, 0.23–0.74; moderate quality evidence) 
    • Appears to be dose dependent with greater reduction when dose was >200 mg/day for PTB<37 weeks (low quality evidence)  
      • OR 0.18 for high dose vs 0.42 for lower dose  
    • No reduction in neonatal death  
  • 17OHPC reduced PTB and neonatal death (no studies assessed PTB <34 weeks) 
    • PTB <37 weeks: OR 0.53 (95% CrI, 0.27–0.95; moderate quality evidence) 
    • Neonatal death: OR 0.39 (95% CI, 0.16–0.95; low quality evidence) 
  • PO Progesterone 
    • PTB <34 weeks: OR 0.42 (95% CI, 0.22-0.83; low quality evidence)  

Short cervix (≤25 mm) 

  • Vaginal progesterone reduced PTB (regardless of history of PTB)  
    • PTB <34 weeks: OR 0.45 (95% CI, 0.24–0.84; low quality evidence) 

CONCLUSION: 

  • Authors recognize limitations of this study including  
    • Sparse data for some subgroups (especially short cervix) 
    • Different interventions and outcomes  
  • In at-risk women, progesterone and 17-OHPC significantly reduced PTB
    • Pessary reduced PTB <37 weeks and risk of PROM and possibly sepsis  
    • Cerclage increased gestational age at birth and reduced PTB <33 weeks  
  • For short cervix, vaginally administered progesterone led to reduced preterm birth in singleton at-risk pregnancies (no/limited data available for other routes)  
  • Overall, vaginal progesterone performed well across all groups, but further research is needed to confirm benefit as well as the finding of reduced neonatal death with 17-OHP  

Learn More – Primary Sources: 

Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis 

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

SMFM Statement: Choice of Progestogen for Preterm Birth Prevention
Does Vaginal Progesterone Improve Birth Outcomes for Mothers with Short Cervix?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site